A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug
conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1)
followed by dose expansion (Phase 2).
The study population in dose escalation (Phase 1) consists of patients with advanced solid
tumors refractory to standard of care, or for whom no standard of care exists. After the MTD
and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor
types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose
escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT
safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to
continue into dose expansion cohorts in select tumor types.